Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis

被引:8
|
作者
Bauer, Alicja
Habior, Andrzej
机构
[1] Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw
[2] Department of Gastroenterology, Hepatology and Clinical Oncology Centre of Postgraduate Medical Education, Warsaw
[3] Clinic of Polish Gastroenterology Foundation, Warsaw
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
primary biliary cholangitis; liver fibrosis; autoantibodies; metalloproteinases; MMP-3; CHRONIC HEPATITIS-C; LIVER FIBROSIS; ANTINUCLEAR ANTIBODIES; EXPRESSION; PROGRESSION; MMPS; ASSOCIATION; ENDOSTATIN; PROGNOSIS; DIAGNOSIS;
D O I
10.3389/fimmu.2022.885229
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and AimsMetalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC. MethodsThe MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit. ResultsHigher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 +/- 62.6 vs 21.3 +/- 7.4 ng/mL, p < 0.001 for healthy subjects; 68.9 +/- 62.6 vs 22.7 +/- 7.6 ng/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 +/- 62.6 vs 37.2 +/- 17.4 ng/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 +/- 85.8 vs 61.6 +/- 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p < 0.01). ConclusionsOur study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Serum matrix metalloproteinase-3 levels in migrainous patients
    Domac, F. Mayda
    Turker, M.
    Mestan, E.
    Adiguzel, T.
    Misirli, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 251 - 251
  • [2] Matrix metalloproteinase-3 serum levels in schizophrenic patients
    Ordak, Michal
    Libman-Sokolowska, Malgorzata
    Nasierowski, Tadeusz
    Badyra, Bogna
    Kaczmarek, Leszek
    Muszynska, Elzbieta
    Bujalska-Zadrozny, Magdalena
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2023, 27 (01) : 1 - 7
  • [3] High serum matrix metalloproteinase-3 and liver stiffness in postoperative biliary atresia
    Sittisak Honsawek
    Kesmanee Praianantathavorn
    Voranush Chongsrisawat
    Paisarn Vejchapipat
    Apiradee Theamboonlers
    Yong Poovorawan
    Pediatric Surgery International, 2011, 27 : 681 - 687
  • [4] High serum matrix metalloproteinase-3 and liver stiffness in postoperative biliary atresia
    Honsawek, Sittisak
    Praianantathavorn, Kesmanee
    Chongsrisawat, Voranush
    Vejchapipat, Paisarn
    Theamboonlers, Apiradee
    Poovorawan, Yong
    PEDIATRIC SURGERY INTERNATIONAL, 2011, 27 (07) : 681 - 687
  • [5] Serum matrix metalloproteinase-3 (stromelysin-l) concentration in patients with chronic liver disease
    Murawaki, Y
    Ikuta, Y
    Okamoto, K
    Koda, M
    Kawasaki, H
    JOURNAL OF HEPATOLOGY, 1999, 31 (03) : 474 - 481
  • [6] Serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis
    Ates, A
    Türkçapar, N
    Olmez, Ü
    Aydintug, O
    Düzgün, N
    Duman, M
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 400 - 400
  • [7] Serum matrix metalloproteinase-3 in patients with psoriasis with and without arthritis
    Taha, Alsayeda A. A.
    Khadr, Nouran A.
    Elneily, Dalia A. E.
    Elkhalifa, Marwa S. A.
    Mohamad, Sara S. M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2023, 20 (02): : 125 - 130
  • [8] Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients
    Tsukahara, S.
    Shinozaki, M.
    Ikari, K.
    Mochizuki, T.
    Inoue, E.
    Tomatsu, T.
    Hara, M.
    Yamanaka, H.
    Kamatani, N.
    Momohara, S.
    RHEUMATOLOGY, 2008, 47 (01) : 41 - 44
  • [9] Serum matrix metalloproteinase-3 in systemic sclerosis
    Jinnin, M
    Ihn, H
    Asano, Y
    Yamane, K
    Yazawa, N
    Tamaki, K
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2004, 296 (01) : 25 - 29
  • [10] Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction
    Samnegård, A
    Silveira, A
    Tornvall, P
    Hamsten, A
    Ericsson, CG
    Eriksson, P
    JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) : 530 - 536